AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00814619 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Patients undergo surgical resection
Study NCT00814619 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Patients undergo radiotherapy
Study NCT00814619 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-dimensional conformal radiation therapy
Description: Patients undergo radiotherapy
Study NCT02687152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: N-hydroxy-nor-L-arginine
Study NCT01610700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW-1000-02
Description: Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. The maximum permitted dose of study medication was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
Study NCT01610700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each actuation of placebo delivered the excipients only.
Study NCT01405391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM01183
Description: PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths, 1 mg and 4 mg vials. Before use, the 1 mg and 4 mg vials should be reconstituted with 2 ml and 8 ml of water for injection respectively, to give a solution containing 0.5 mg/ml PM01183. For administration to patients as an i.v. infusion, reconstituted vials are diluted with glucose 50 mg/ml (5%) solution for infusion or sodium chloride 9 mg/ml (0.9%) solution for infusion.
Study NCT02039817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDN-6556
Study NCT03150134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Patients with advanced AML received early tapering of immunosuppressive drugs(Cyclosporine)
Study NCT03150134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: routine reduction of immunosuppressive drugs(cyclosporine)
Description: patients with AML in CR were given the routine reduction of immunosuppressive drugs(cyclosporine)
Study NCT01558869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1200 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)
Study NCT01558869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 70 mg/m2 IV on day 1 of a 2-week cycle
Study NCT01558869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 130 mg/m2 IV on day 1 of a 2-week cycle
Study NCT02018159 — intervention group
Intervention type: DRUG
Intervention: menotropin
Study NCT01318200 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial Chemoembolization
Description: Transarterial Chemoembolization will be given within 12 weeks and up to 3 staged procedures, depending on the architecture of the tumor vasculature.
Study NCT01318200 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CyberKnife SBRT
Description: Dose is 45 Gy (15 Gy in 3 fractions) or 36 Gy(12 Gy in 3 fractions). Tumors should receive the higher dose unless normal tissue constraints cannot be met.
Study NCT04383080 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: acupuncture at specific acupuncture points
Study NCT04383080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Description: low level laser emission on specific acupuncture points
Study NCT00670267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nadolol
Description: Nadolol, oral taken daily, doses will be escalated every two weeks over 13 weeks following a 2 week run-in.
Study NCT02357407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patients in intensive care : infection treated with ciprofloxacin IV
Description: 8-10 samples per patients on day-4 of their treatment
Study NCT02357407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osteoarticular infected patients : infection treated with oral ofloxacin
Description: 8-10 samples per patients on day-4 of their treatment
Study NCT01766310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: yellow tablet contained 5mg of folic acid, manufactured from the Government Pharmaceutical Organization, Ministry of Public Health, Thailand
Study NCT01766310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sugar tablet manufactured to mimic folic acid tablet
Study NCT01523769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Milking
Description: Approximately 10 cm of umbilical cord was milked toward the baby immediately following delivery. (The blood remaining in the umbilical cord after delivery is squeezed in the direction from the placenta (remaining inside the uterus) toward the newborn baby.)
Study NCT00004161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenretinide
Study NCT00004161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02688309 — intervention group
Intervention type: DRUG
Intervention: Ozurdex
Description: Patients from the clinic will be considered for enrollment if they are receiving an intraocular injection of a steroid as part of standard care for macular edema or progressive fibrosis. Clinic patients who are receiving an intraocular injection of steroid (Ozurdex) as part of standard care who agree to participate will have an AC tap just prior to the intraocular injection of steroid and a second AC tap at a follow up visit 6 ± 2 weeks after the steroid injection.
Study NCT02688309 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: The 60 patients from the operating room will be patients undergoing surgery for one of the following conditions: (1) Proliferative Diabetic Retinopathy, (2) rhegmatogenous retinal detachment with PVR, (3) rhegmatogenous retinal detachment without PVR, (4) macular pucker, (5) macula hole. All patients will be administered an AC (Anterior Chamber) tap just prior to the surgical procedure while in the OR.
Study NCT02688309 — intervention group
Intervention type: PROCEDURE
Intervention: Anterior Chamber (AC) Tap
Description: A paracentesis removing about 0.1 ml of fluid from the front part of the eye (the aqueous chamber) will be performed in the operating room just prior to surgery or in the clinic. In the operating room, the AC tap is done after the eye is anesthetized and cleaned with 5% povidone iodine for the surgery. A 30-gauge needle attached to a tuberculin syringe is inserted into the AC and 0.1 ml of aqueous is removed. The wound is self-sealing and has no effect on the surgery. In the clinic, the AC tap is done after drops of proparacaine and 5% povidone iodine is placed in the eye and a lid speculum is inserted. The patient is seated at a slit lamp and a 30-gauge needle attached to a tuberculin syringe is inserted into the AC and 0.1 ml of aqueous is aspirated and then the needle is removed.
Study NCT01846832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 150 mg taken orally (by mouth) as a capsule with food once daily for 12 weeks.
Study NCT01846832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a (PegIFNα-2a)
Description: 180 mcg administered according to the manufacturer's prescribing information as a 0.5 mL subcutaneous (under the skin) (SC) injection once a week in the morning or evening for up to 24 weeks.
Study NCT01846832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: 1000 mg or 1200 mg administered according to the manufacturer's prescribing information for up to 24 weeks. If the participant's baseline body weight is \< 75 kg, the total daily dose of RBV will be 1000 mg, administered orally (by mouth) as 400 mg (2 tablets of 200 mg, intake with food) in the morning and 600 mg (3 tablets of 200 mg, intake with food) in the evening. If the baseline body weight is > or = 75 kg, the total daily dose will be 1200 mg, administered as 600 mg in the morning and evening (3 tablets of 200 mg per intake, with food).
Study NCT03422003 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: For the conventional fractionation arm: Each fraction will consist of 200 cGy per day. Total dose = 5000 cGy to the chest wall and 4600-5000 cGy to the lymph nodes.~For the hypofractionation arm: Each fraction consists of 266 cGy per day. Total dose = 4256 cGy to the chest wall and 3990 cGy to the lymph nodes.
Study NCT03422003 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: For the conventional fractionation arm: Each fraction will consist of 200 cGy per day. Total dose = 5000 cGy to the chest wall and 4600-5000 cGy to the lymph nodes.~For the hypofractionation arm: Each fraction consists of 266 cGy per day. Total dose = 4256 cGy to the chest wall and 3990 cGy to the lymph nodes.
Study NCT04789811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercise
Description: Stretching exercise: Stretching exercises were planned for 30 seconds, ten repetitions for each stretching, 10 minutes in total, four days a week, for two weeks.
Study NCT04789811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling: A total of 3 sessions of dry needling, once a week, were applied to the gastrocnemius muscle.
Study NCT00520416 — intervention group
Intervention type: PROCEDURE
Intervention: Carbon dioxide angiogram
Description: see description of procedure
Study NCT01474603 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: n-3 PUFA in protein-enriched low-GI diet
Description: 3 g per day n-3 polyunsaturated fatty acids in a protein-enriched low-GI diet
Study NCT01515085 — intervention group
Intervention type: PROCEDURE
Intervention: laser interstitial thermal therapy
Description: residual gliomas either after debulking or biopsy evaluated for intervention with laser ablation prior to onset of adjuvant therapy
Study NCT05424419 — intervention group
Intervention type: PROCEDURE
Intervention: Brace therapy
Description: A Chêneau-type brace was made to be worn as a full-time brace or during daytime only (double-brace group), whereas the nighttime brace was produced according to the Charleston approach.
Study NCT01716247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mammography (CESM) and MRI
Description: The study consists of the addition of a single contrast enhanced digital mammography examination (CESM) to the routine screening of a woman at increased risk for breast cancer who is also having a breast MRI. Breast MRIs will be read by the radiologist reading breast MRIs on any given day. CESM is a dedicated system, derived from a standard digital mammography unit modified to deliver the dual or multiple energy exposures and visualization of combined images after IV contrast administration. If the patient is having her routine mammogram within 30 days of her MRI, CESM can replace that mammogram Patients will be randomly assigned to one of the radiologists trained to interpret CESM. That radiologist will read the CESM blinded to the results of the breast MRI.This process will be monitored by the research assistant No radiologist will read both the breast MRI and CESM on the same patient.
Study NCT01361412 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ToleroMune Ragweed
Description: Intradermal administration 1x8 administrations, 2 weeks apart
Study NCT01361412 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal injection 1x8 administrations, 2 weeks apart
Study NCT03593083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low altitude: 470m above sea level
Description: Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
Study NCT02120118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 30mg/m2
Study NCT02120118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: 20mg/m2
Study NCT04256057 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Magnesium Sulfate
Description: After the induction of anesthesia, a loading dose of magnesium sulfate 50mg/kg in 100mL of isotonic saline as within 5 to 10 minutes(23) followed by a maintenance dose of 10 mg/kg/hr up to the end of surgery
Study NCT01858129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental group: Budicort by Inhalation
Description: Inhaled Budicort twice daily
Study NCT01858129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02995694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Estradiol Vaginal Cream
Study NCT02995694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo with no active pharmaceutical ingredients. Topical vaginal cream
Study NCT02995694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference
Description: Estrace Vaginal Cream
Study NCT04235764 — intervention group
Intervention type: DEVICE
Intervention: modified resectoscope
Description: The modified resectoscope will be used post cystectomy (En-bloc TURBT) to resect areas of the tumor from the cystectomy specimen. These resected tumors will be sent for histopathology to assess the size of resection, depth of resection, and ability to ascertain tumor orientation and compared to the remainder of the cystectomy specimens to see if the modified resectoscope can provide improved pathologic standards for the TURBT procedure.
Study NCT04235764 — intervention group
Intervention type: PROCEDURE
Intervention: TURBT
Description: All patients will receive routine surgical transurethral resection of bladder tumors (TURBT).
Study NCT03593083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Säntis; 2500m above sea Level
Description: Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
Study NCT04201847 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum test
Description: Serum Fetuin A and fetuin B
Study NCT02334735 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC Vaccine
Description: DCs pulsed with 100µg/mL peptide (NY-ESO-1 and Melan-A/MART-1)~10 to 15 x 106 DCs per peptide antigen (NY-ESO-1 and Melan-A/MART-1) (total not to exceed 50 x 10\^6 cells)
Study NCT02334735 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Montanide Vaccine
Description: 250 µg peptide (NY-ESO-1 and Melan-A/MART-1) and 1.1 mL Montanide ISA-51 VG
Study NCT02334735 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: 1.4 mg
Study NCT01758315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training and in-office coaching
Description: Participating practices will be coached to perform rapid, small-scale tests of change and to iteratively improve performance of problem-prone care systems, as well as to imbed simple measurement in routine daily work streams to guide improvement efforts. The sixteen intervention practices will serve as realistic research laboratories to help advance malpractice risk prevention and patient safety in specific areas by refining tools and strategies for smaller practices.
Study NCT02334735 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Poly-ICLC
Description: 1.4 mg
Study NCT01877447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Current Stimulation with cathodal stimulation over right dorsolateral prefrontal cortex. Anodal stimulation over left deltoid region
Study NCT03028168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yôga
Description: Intervention observing respiratory frequency (RF) of 15- 20 respiratory cycles per minute (rcpm). A standardized 7-minute final relaxation .
Study NCT03028168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing technique
Description: Intervention uses diaphragmatic breathing, observing slow respiratory frequency, between 5-8 rcpm. A standardized 7-minute final relaxation.
Study NCT03028168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: Patients will be oriented to keep their pharmacological routine and daily activities, with no structured exercises. They will have to return to the hospital for post-testing after 8 weeks from randomization
Study NCT02595203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C-pos 1]-Debio 1450 BES Solution
Description: A solution containing Debio 1450 bis ethanolamine salt (BES) radiolabelled with carbon-14 (14C) at position 1
Study NCT02595203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C-pos 25]-Debio 1450 BES Solution
Description: A solution containing Debio 1450 BES radiolabelled with carbon-14 (14C) at position 25
Study NCT04944875 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group headphone
Description: The patients in the first group wore the headphones but did not listen the music or maternal voice. The standard sedation method was applied to all patients.
Study NCT04944875 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group music
Description: The patients in the second group listened to classical music (Vivaldi's The Four Seasons violin concertos) by sound- isolating headphones through the procedure.The standard sedation method was applied to all patients.
Study NCT04944875 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group maternal voice
Description: The patients in the third group listened to maternal voice by sound- isolating headphones through the procedure.The standard sedation method was applied to all patients.
Study NCT04101799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: For Our Children's Sake
Description: Parental support with the aim to support positive parenting and promote healthy child development. Conducted in group-format with weekly 2.hour sessions conducted by trained group leaders according to a programme manual.
Study NCT04101799 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Participating in everyday activities that may include parenting activities in the control prisons
Study NCT04120506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VPRIV
Description: Safety, pharmacokinetics, and efficacy of rapid intravenous infusion of velaglucerase alfa (VPRIV) in adult patients with type 1 Gaucher disease
Study NCT02298218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: The intervention drug, meloxicam is safe medicine which is used to treat pain or inflammation caused by osteoarthritis or rheumatoid arthritis in adults and children who are at least 2 years old. It may also be used for purposes not listed in the medication guide. It will be taken once a daily with a dose of 0.125 mg/kg/day (high-dose group) or 0.06 mg/kg/day (low-dose group). After 6 months of medication, the maintenance will be decided by the comparison of liver stiffness score before and after the intervention.
Study NCT02199847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmaton® Caplets
Study NCT02199847 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00354354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combivent
Description: Nebulized Combivent (4 mL) or saline solution (0.9% NaCl) (4 mL) will be administered once only to subjects.
Study NCT00354354 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Combivent
Description: Nebulized Combivent (4 mL) or saline solution (0.9% NaCl) (4 mL) will be administered once only to subjects.
Study NCT00373789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A, bladder detrusor muscle injection
Description: 200 U provided as a total of 6 cc of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization. Injections will be spread out to equally cover the entire dome of the bladder, but spare the bladder trigone and ureteral orifices.
Study NCT00373789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle saline as placebo
Description: A total of 6 cc of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization. Injections will be spread out to equally cover the entire dome of the bladder, but spare the bladder trigone and ureteral orifices
Study NCT01888315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal denervation with Symplicity Flex Medtronic/Ardian
Description: Renal denervation using CE-marked devices will be performed according to best medical practice.
Study NCT01888315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal denervation with EnligHTN St. Jude Medical
Description: Renal denervation using CE-marked devices will be performed according to best medical practice.
Study NCT01888315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal denervation with Paradise Recor
Description: Renal denervation using CE-marked devices will be performed according to best medical practice.
Study NCT01888315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal denervation with V2 Vessix
Description: Renal denervation using CE-marked devices will be performed according to best medical practice.
Study NCT02907333 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advice to use condoms
Study NCT02807948 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pacemaker, ICD, or CRT device
Description: MRI Scans on SJM device implanted subjects for clinical purpose